208 related articles for article (PubMed ID: 37630410)
1. Preclinical Evaluation of a New Series of Albumin-Binding
Boinapally S; Alati S; Jiang Z; Yan Y; Lisok A; Singh R; Lofland G; Minn I; Hobbs RF; Pomper MG; Banerjee SR
Molecules; 2023 Aug; 28(16):. PubMed ID: 37630410
[TBL] [Abstract][Full Text] [Related]
2. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of
Banerjee SR; Minn I; Kumar V; Josefsson A; Lisok A; Brummet M; Chen J; Kiess AP; Baidoo K; Brayton C; Mease RC; Brechbiel M; Sgouros G; Hobbs RF; Pomper MG
J Nucl Med; 2020 Jan; 61(1):80-88. PubMed ID: 31253744
[TBL] [Abstract][Full Text] [Related]
5. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
[TBL] [Abstract][Full Text] [Related]
6. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
[TBL] [Abstract][Full Text] [Related]
7. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.
Kelly J; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; Schlyer D; Zhao Y; Kim D; Babich JW
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1841-1851. PubMed ID: 29623376
[TBL] [Abstract][Full Text] [Related]
8.
Banerjee SR; Kumar V; Lisok A; Chen J; Minn I; Brummet M; Boinapally S; Cole M; Ngen E; Wharram B; Brayton C; Hobbs RF; Pomper MG
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2545-2557. PubMed ID: 31399803
[TBL] [Abstract][Full Text] [Related]
9. Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin.
Reissig F; Zarschler K; Novy Z; Petrik M; Bendova K; Kurfurstova D; Bouchal J; Ludik MC; Brandt F; Kopka K; Khoylou M; Pietzsch HJ; Hajduch M; Mamat C
Theranostics; 2022; 12(17):7203-7215. PubMed ID: 36438496
[No Abstract] [Full Text] [Related]
10.
Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
[TBL] [Abstract][Full Text] [Related]
11. Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands.
Kuo HT; Zhang Z; Zhang C; Merkens H; Tan R; Wong AAWL; Uribe CF; Bénard F; Lin KS
Theranostics; 2023; 13(13):4559-4573. PubMed ID: 37649602
[TBL] [Abstract][Full Text] [Related]
12. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for
Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution and dosimetry of a single dose of albumin-binding ligand [
Kramer V; Fernández R; Lehnert W; Jiménez-Franco LD; Soza-Ried C; Eppard E; Ceballos M; Meckel M; Benešová M; Umbricht CA; Kluge A; Schibli R; Zhernosekov K; Amaral H; Müller C
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):893-903. PubMed ID: 32949253
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Investigations to Explore the Difference between the Diastereomers [
Borgna F; Deberle LM; Busslinger SD; Tschan VJ; Walde LM; Becker AE; Schibli R; Müller C
Mol Pharm; 2022 Jul; 19(7):2105-2114. PubMed ID: 35544699
[TBL] [Abstract][Full Text] [Related]
15. Combined Application of Albumin-Binding [
Borgna F; Deberle LM; Cohrs S; Schibli R; Müller C
Mol Pharm; 2020 Jun; 17(6):2044-2053. PubMed ID: 32383887
[TBL] [Abstract][Full Text] [Related]
16. Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile.
Deberle LM; Tschan VJ; Borgna F; Sozzi-Guo F; Bernhardt P; Schibli R; Müller C
Molecules; 2020 May; 25(11):. PubMed ID: 32486054
[TBL] [Abstract][Full Text] [Related]
17. An Improved
Mease RC; Kang CM; Kumar V; Banerjee SR; Minn I; Brummet M; Gabrielson KL; Feng Y; Park A; Kiess AP; Sgouros G; Vaidyanathan G; Zalutsky MR; Pomper MG
J Nucl Med; 2022 Feb; 63(2):259-267. PubMed ID: 34088772
[TBL] [Abstract][Full Text] [Related]
18. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
[TBL] [Abstract][Full Text] [Related]
19. Hetero-bivalent agents targeting FAP and PSMA.
Boinapally S; Lisok A; Lofland G; Minn I; Yan Y; Jiang Z; Shin MJ; Merino VF; Zheng L; Brayton C; Pomper MG; Banerjee SR
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4369-4381. PubMed ID: 35965291
[TBL] [Abstract][Full Text] [Related]
20. Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors.
Vaidyanathan G; Kang CM; McDougald D; Minn I; Brummet M; Pomper MG; Zalutsky MR
Nucl Med Biol; 2018; 62-63():18-30. PubMed ID: 29803076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
